Global Pharmaceutical Company Strengthens T&E Compliance and Reduces Risk with Oversight

Business Challenge

Despite having established audit processes in place, the finance and compliance teams faced growing pressure from: Industry: Manufacturing – Pharmaceuticals Revenue: $63B Profile: Global, highly regulated enterprise operating across regions, currencies, and expense systems. High transaction volumes that made it difficult to consistently identify meaningful risk. Duplicate and non-compliant expenses that continued to surface after payment. Out-of-pocket and personal spend creating compliance exposure in higher-risk regions. Manual review effort that slowed audits and distracted teams from higher-value work Leadership needed clearer visibility into where risk was occurring, confidence that controls were working, and proof that audit efforts were actually changing employee behavior.

Solution

The Oversight Approach: Earlier Detection, Better Focus Oversight supported the organization’s compliance objectives by serving as a centralized control layer across T&E and corporate card activity. 

Post-payment monitoring at scale Oversight continuously analyzed transactions to surface non-compliant spend, duplicate expenses, and policy misuse that traditional controls missed.

Pattern-based risk detection Rather than reviewing transactions in isolation, Oversight identified repeat behaviors across employees, merchants, and regions—helping auditors focus on systemic issues.

Targeted employee engagement Automated policy education emails reinforced expectations and corrected behavior without requiring manual follow-up from auditors.

Focused escalation Only the most serious issues were escalated to corporate audit, preserving audit capacity while strengthening governance. 

Results

The program results delivered clear, enterprise-scale impact:

$8.8M in confirmed non-compliant spend identified 
across T&E and card programs$203K in confirmed duplicate expenses flagged
$164K reimbursed back to the organization from 
duplicate expenses
$205K in total reimbursements identified (inclusive 
of duplicates)
$697K in non-compliant personal spend uncovered
$56K in high-risk issues escalated to corporate audit

Benefits

Evidence of Behavior Change: Partnering with Oversight produced clear signs of improved employee behavior: Employees who received Oversight 
compliance communications saw a 36% reduction in finding rates. Over the same period, the general employee population experienced an increase in findings. Overall findings rates declined in FY25, indicating improving compliance habits over time.

Why It Matters: For finance and audit leaders, the value went beyond individual findings. Audit teams stayed focused on meaningful risk, not low-value review. Leadership gained clear, defensible metrics to demonstrate program effectiveness. Compliance controls scaled globally without increasing headcount. Risk was identified earlier, reducing exposure and strengthening governance

Oversight helped this global pharmaceutical company strengthen compliance, recover value, and influence employee behavior—at a scale few organizations can manage manually. By combining continuous monitoring, pattern-based detection, and targeted engagement, the company improved audit efficiency while reducing risk across its T&E and card programs. Oversight is now a foundational part of the organization’s control environment—supporting sustained compliance, clearer accountability, and confident decision-making